Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A

SSSE:600436
130.88
CNY
+0.75
(+0.58%)
2.09EPS
54.08P/E
71.19BMarket Cap
Apr 12Next Earn
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A
SSE:600436
(Shanghai Stock Exchange)

Recent

price

130.88

P/E

ratio

54.08

div

yld

1.23%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.5
1.76
2.02
2.36
2.41
3.11
3.83
6.17
7.88
9.49
10.79
13.29
14.42
16.68
17.87
14.93
13.1
Revenue per Share
0.34
0.44
0.6
0.73
0.73
0.77
0.89
1.34
1.89
2.28
2.77
4.03
4.1
4.64
4.93
3.58
2.18
Basic EPS, GAAP
0.29
0.34
0.01
0.22
0.4
0.37
0.5
1.04
0.89
-1.57
1.74
0.61
11.11
3.42
0.41
-0.44
- -
Free Cash Flow per Basic Share
0.13
0.18
0.18
0.22
0.32
0.27
0.28
0.33
0.47
0.65
0.87
0.94
1.26
1.3
3.52
3.26
1.6
Dividend per Share
1.81
1.98
2.59
3.94
4.82
5.23
5.79
6.86
8.31
10.99
13.03
16.09
18.78
22.17
23.66
24.1
23.46
Book Value per Share
1.7
1.88
2.43
3.73
4.54
4.96
5.27
6.5
8.1
10.73
12.6
15.72
18.25
21.69
23.2
23.66
22.89
Tangible Book Value per Share
579
580
581
590
604
606
602
602
605
603
603
603
603
603
604
603
604
Basic Weighted Avg Shares
867
1,022
1,171
1,396
1,454
1,886
2,309
3,714
4,766
5,722
6,511
8,022
8,694
10,058
10,788
9,001
7,909
Sales/Revenue/Turnover
23.3
29.98
34.1
35.85
30.2
27.69
26.3
24.32
26.28
27.67
28.12
34.63
32.93
32.43
31.9
25
19.7
Operating Margin (%)
18
19
20
22
29
33
46
65
60
56
90
133
80
102
95
121
- -
Depreciation Expense
194
255
349
430
439
467
536
807
1,143
1,374
1,672
2,432
2,472
2,797
2,977
2,159
1,317
Net Income, GAAP
16.19
15.85
15.58
15.39
15.4
15.71
16.81
17.11
14.97
15.67
14.63
14.09
15.27
15.37
15.35
15.55
16.23
Effective Tax Rate (%)
22.38
24.95
29.76
30.79
30.18
24.75
23.22
21.73
23.98
24.02
25.67
30.32
28.44
27.81
27.6
23.98
16.65
Profit Margin (%)
473
579
955
1,963
2,120
2,462
2,502
3,067
3,939
5,603
6,473
8,496
10,195
12,217
8,955
8,544
10,739
Working Capital
30
- -
314
298
299
299
300
- -
- -
- -
106
87
109
143
213
184
160
LT Debt
1,084
1,189
1,556
2,455
2,987
3,303
3,751
4,425
5,305
6,970
8,257
10,138
11,824
13,920
14,839
15,088
14,660
Total Equity
16.77
19.99
20.02
17.52
13.89
12.95
12.36
16.79
20.56
19.9
19.71
24.25
20.86
20.32
19.33
13.37
- -
Return on Invested Capital (%)
17.45
20.46
22.35
18.91
14.99
13.98
14.59
18.37
21.87
20.46
20
24.12
20.49
19.81
19.25
13.7
- -
Return on Capital (%)
20.72
23.16
26.29
22.17
16.61
15.39
16.13
21.16
24.98
23.6
23.07
27.69
23.51
22.64
21.53
14.98
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
886
861
861
LT Borrowings
52
52
48
LT Finance Leases
130
121
112
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
603
603
603
Market Capitalization
91,161
65,931
71,191

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
11,428
11,158
13,480
Cash, Cash Equivalents & STI
1,957
2,114
2,226
Accounts Receivable, Net
892
1,018
863
Inventories
6,278
5,954
5,696
Total Current Liabilities
2,276
3,018
2,741
Payables & Accruals
- -
- -
- -
ST Debt
886
861
861
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.67%
13.09%
1.68%
Free Cash Flow
92%
256.12%
-207.07%
Net Income, GAAP
18.81%
7.85%
-27.49%
Sales/Revenue/Turnover
18.34%
7.59%
-16.56%
Total Cash Common Dividend
34.67%
41.87%
-7.5%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,171
2,480
2,800
2,338
10,788
2025
3,142
2,237
- -
1,559
9,001
2026
2,741
1,832
1,777
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.62
1.24
1.6
0.48
4.93
2025
1.66
0.73
- -
0.05
3.58
2026
1.23
0.58
0.32
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
2.33
0.01
1.17
3.52
2025
0.01
0.01
- -
0.02
3.26
2026
0.01
0.01
1.58
- -
- -
Business
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436.SS) manufactures and sells traditional Chinese medicines under the Pien Tze Huang brand, along with related healthcare products; its core offerings include flagship Pien Tze Huang tablets and capsules for clearing heat, removing toxins, and treating abscesses, boils, and traumatic injuries, as well as Angong Niuhuang Pills, Yindan Pinggan Capsules, Liuwei Dihuang Pills, Chuangbei Qingfei Syrup, Xinshubao Tablets, Heat-clearing and cough-relieving granules, Huoxiang Zhengqi water and capsules, and Bezoar detoxification tablets; the company also produces health foods, beverages, cosmetics, daily chemical products, Chinese herbal decoction pieces, medical equipment, and tonics targeting liver diseases, respiratory conditions, cardiovascular issues, colds, and dermatology. Founded in 1956 through the restructuring of Zhangzhou Pharmaceutical Factory and listed on the Shanghai Stock Exchange in 2003, the company maintains headquarters in Zhangzhou, Fujian province, China, and operates primarily in the domestic market with exports to over 30 countries including Singapore, Thailand, Malaysia, Canada, Brazil, and Argentina. Zhangzhou Pientzehuang functions as a subsidiary of Zhangzhou Jiulongjiang Group Co Ltd and supports multiple R&D platforms such as a National Enterprise Technology Center and provincial engineering centers; it serves pharmaceutical retail, hospitals, and international markets through 34 holding subsidiaries, eight joint-stock companies, and four industry funds. Recent developments include a February 2024 cooperation agreement with Beijing Tong Ren Tang Group to promote traditional Chinese medicine globally; accelerated expansion of Zhangzhou Pientzehuang Chinese Patent Medicine outlets with over 30 new sites in Q1 2025 and plans for 600 more nationwide; a 200 million yuan investment in the Gaoxin Runxin Healthcare Industry Investment Partnership in 2025 targeting pharmaceuticals, medical devices, and synthetic biology; new product launches such as health-preserving beverages and skin-rejuvenating cosmetics for younger consumers; clinical trials for PZH2108 in liver cancer and PZH2111 for FGFR abnormalities; and selection as one of China's brands favored by foreigners in 2024.